Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

Phase II Study of Oxaliplatin and CPT-11 as First Line Treatment for Extensive Stage Small Cell Lung Cancer

The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.

Inclusion Criteria:

• Previously untreated extensive small cell lung cancer
• No prior chemotherapy
• No prior radiotherapy except for the treatment of brain metastases

Exclusion Criteria:

• Prior treatment for extensive stage small cell lung cancer
• Known hypersensitivity to any of the components of oxaliplatin or CPT-11
• Greater than grade 2 peripheral neuropathy
• Known HIV or Hepatitis B or C (active, previously treated or both)